Appeal announcement - Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma

The Final Appraisal Determination for this technology appraisal is being returned to the Appraisal Committee for reconsideration and therefore the appeal hearing, scheduled for 18 September 2006, has been cancelled.

A miscalculation in the glioma model developed by the assessment group has been discovered.  In these circumstances, the Institute has decided to ask the Appraisal Committee to consider revised analysis.  The revised analysis will be circulated to consultees and commentators in advance of the committee meeting.  Comments on the revised analysis will be presented to the committee to inform their deliberations.

The date of the next Committee meeting will be 22 November 2006.

This page was last updated: 30 March 2010